Background: Treatment-Emergent Suicidal Ideation (TESI) in older adults is poorly understood. We characterized TESI in older depressed adults during treatment with venlafaxine and explored whether TESI is related to antidepressant exposure versus dimensions of the psychiatric illness. We examined the relationship among medication exposure, onset of TESI, and clinical characteristics. Methods: We analyzed data on 233 clinical trial participants with major depression and no baseline suicidal ideation who were treated for up to 12 weeks with venlafaxine XR (target dose: 150-300 mg/day). Suicidal ideation was assessed weekly with the Scale for Suicide Ideation. A Kaplan-Meier curve displayed the time course of TESI. Differences in baseline demographic and clinical variables between the TESI and Non-TESI groups were assessed with analyses of covariance or logistic regression. A final multivariate logistic regression model indicated baseline predictors of TESI. Depression treatment outcomes in subjects developing TESI versus those who did not were examined with a mixed effects model. Results: TESI occurred in 10% of participants, typically with onset within 4 weeks of the start of treatment. Anxiety, and depression severity at baseline were predictors of TESI. Most TESI was mild and transient, with 6/233 participants having TESI considered clinically meaningful. TESI was not associated with venlafaxine blood levels or side effects. Conclusions: In older depressed adults, TESI is relatively uncommon and it is likely related to the underlying illness rather than to a medication adverse effect. This suggests that TESI requires continuing rather than discontinuing antidepressant treatment.
Introduction
Suicidal ideation and behavior can emerge during depression treatment. This problem, called TreatmentEmergent Suicidal Ideation (TESI), received recognition after a large meta-analysis carried out by the Food and Drug Administration (FDA) found an increased risk for suicidal thinking and behavior in younger patients treated with antidepressants compared with those who received a placebo (Hammad et al., 2006) . Subsequent data indicated that the risk of TESI was limited to those under 25 years old, with no increased risk for those 25-64 years old, and a reduced risk in those 65 years and older (Stone et al., 2009) . These meta-analyses led to a Food and Drug Administration "black-box" warning regarding TESI in adolescents and young adults and a recommendation for close monitoring for suicidality in all depressed patients being treated with antidepressants.
TESI remains poorly characterized and understood, particularly in older adults. When it occurs, TESI is more likely to occur during the first weeks of antidepressant treatment (Juurlink et al., 2006; Jick et al., 2004) . In a recent study, TESI was associated with initiation of treatment at higher doses, suggesting a direct pharmacological cause (Miller et al., 2014) . Furthermore, antidepressant's adverse effects such as akathisia, anxiety, and agitation have been proposed as potential causative factors for TESI (Rothschild and Locke, 1991; Hansen and Wilkinson, 2001; Akiskal et al., 2005; Szanto et al., 2007) . Several risk factors for TESI are associated with illness severity: history of suicidal behavior, having been treated with more than one antidepressant (a proxy for treatment resistance), depression severity, and non-response to treatment in the index episode (Szanto et al., 2007; Jick et al., 2004; Jick et al., 1992; Perroud et al., 2009; Zisook et al., 2009; Perlis et al., 2007) .
We analyzed data from the Incomplete Response in Late-life Depression: Getting to Remission ("IRL-GREY") clinical trial (Lenze et al., 2015) to characterize TESI in older depressed adults treated openly with venlafaxine. We addressed the overarching question of whether TESI represents an antidepressant adverse effect versus a dimension of the underlying psychiatric illness. First, we examined whether TESI is related to medication levels and adverse effects (such as psychomotor agitation); next, we explored whether TESI is correlated with baseline clinical characteristics such as illness severity, chronicity, anxiety, and high burden of medical illness. In addition, given increasing literature indicating an association between cognitive deficits and suicidal vulnerability in older adults (Gujral et al., 2013; Gujral et al., 2016; RichardDevantoy et al., 2014) , we examined baseline global and cognitive function and executive function correlates in TESI.
Methods

Participants
This analysis focuses on the open-label initial treatment phase of the NIMH-sponsored IRL-GREY study. Detailed methods have been reported and are summarized briefly here (Lenze et al., 2015) . Between July 20, 2009 and May 15, 2014, we recruited adults aged 60 and older from the community via media advertisement, research registries, or referrals from primary care and specialty geropsychiatric clinics at three sites (University of Pittsburgh, Centre for Addiction and Mental Health at the University of Toronto, and Washington University in St. Louis). Approval from the three sites' Institutional Review Boards was obtained and all participants provided written informed consent.
Participants had a diagnosis of Non-psychotic Major Depressive Disorder (MDD) based on the Structured Clinical Interview (SCID) for DSM-IV (First et al., 1997) and a score ≥15 on the Montgomery-Asberg Depression Rating Scale (MADRS) (Montgomery and Asberg, 1979) . Exclusion criteria included current psychosis; lifetime diagnosis of bipolar disorder, schizophrenia, schizoaffective disorder, or dementia; cognitive impairment as evidenced by a score ≤20 on the Mini-Mental Status Examination (Cockrell and Folstein, 1988) ; alcohol or substance abuse within the past 3 months; high suicide risk and refusal to be hospitalized; unstable physical illness; or a contraindication to venlafaxine XR or aripiprazole.
Assessments
Participants were assessed at baseline (pre-treatment) and on a weekly basis with the MADRS, the Brief Symptom Inventory anxiety subscale (BSI-anxiety; Derogatis and Melisaratos, 1983) , the UKU side effect rating scale (Lingjaerde et al., 1987) and the 21-item Scale for Suicide Ideation (SSI; Beck et al., 1979) . The Penn State Worry Questionnaire, abbreviated version (PSWQ-A; Meyer et al., 1990) and the Anxiety Sensitivity Index (ASI; Mohlman and Zinbarg, 2000) were obtained at baseline and at 12 weeks.
Burden of co-morbid physical illness was assessed at baseline with the Cumulative Illness Rating Scale for Geriatrics (CIRS-G; Miller et al., 1992) . Baseline neurocognitive function including immediate memory, delayed memory, language, attention, and visuospatial/ constructional ability was assessed with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS; Randolph et al., 1998) . Baseline executive function was assessed with the Delis Kaplan Executive Function Scale (DKEFS; Delis et al., 2001) Intervention Participants were treated under open label condition with venlafaxine XR, starting at 37.5 mg/day and titrated to a target dose of 150 mg/day over 2 weeks or more slowly based on tolerability. After 6 weeks, venlafaxine was titrated up to 300 mg/day if the MADRS score was still above 10. Venlafaxine dose could be lowered because of side effects.
Pharmacotherapy was embedded in a model of depression care management; supportive clinical care focused on psychoeducation about depression and it's treatment, depressive symptoms, suicidal ideation, countermeasures for medication adverse effects, and treatment adherence (Reynolds et al., 2010) . Medication levels were obtained after 4 weeks of treatment. Serum levels of venlafaxine and its active metabolite O-desmethylvenlafaxine (norvenlafaxine) were measured as described in Shea and colleagues (Shea et al., 2013) . Participants were allowed to continue outside psychotherapies and some pre-existing medications for anxiety or sleep (low-dose benzodiazepines, zolpidem, eszopiclone, trazodone, or very lowdose tricyclic antidepressant).
Analysis
Of 468 IRL-GREY participants, 33 were excluded because they were already taking venlafaxine, seven withdrew within the first week of starting venlafaxine and had no follow-up data, one was excluded due to missing baseline data, and 194 reported suicidal ideation at baseline. Thus, the sample comprised 233 participants without suicidal ideation at baseline, consistent with the intent to examine TESI.
We defined TESI as absence of suicidal ideation (total SSI score = 0) at baseline and having at least one SSI total score ≥1 during subsequent treatment with venlafaxine. To further assess the severity of TESI, we also examined the scores on MADRS item 10 (suicide item) at the time of TESI with a score of 0 indicating no suicidal ideation or thoughts of death; 2, fleeting suicidal thoughts; 4, suicidal thoughts are common; 6, explicit plans/active preparations for suicide. In this analysis, remission was defined as a MADRS score of 10 or less at the last visit.
All data were examined for normality and transformations were used where necessary. A Kaplan-Meier curve was used to display time to onset of TESI. Baseline demographic and clinical differences between TESI and Non-TESI groups were tested using analysis of covariance (ANCOVA) for continuous variables and logistic regression for dichotomous variables (gender, race, and recurrent depression). We included site as a covariate in all analyses; when frequency was too small to control for site, the Fisher Exact p-value was reported. A final multivariate logistic regression model was created to examine baseline predictors of TESI. A linear mixed effects model examined the relationship between worsening or depression or worsening of anxiety and TESI. Treatment outcomes to assess depression improvement in those who developed TESI versus those who did not were examined using a mixed effects model. Other outcomes including study withdrawals due to side effects and study withdrawals due to other reasons were compared with chi-square tests. We used SAS (version 9.4) and IBM SPSS (version 23) to analyze the data with p-values < 0.05 considered statistically significant.
Results
Proportion of participants developing TESI
Of the 233 participants included in this study, 24 (10%) developed TESI. As shown in Figure 1 , the onset of TESI usually occurred early in treatment, with most cases within 4 weeks of venlafaxine initiation. Frequencies of SSI scores in TESI subjects were as follows: 19 subjects had a SSI score of 1 indicating a low severity of suicidal ideation, one subject had a score of 2, one subject had a score of 8, one subject had a score of 10, one subject had a score of 11 and one subject had a score of 20. Similarly, among those with TESI, the MADRS item 10 scores were low (mean + SD: 1.1 + 1.0; median = 1; range 0-4). There was one suicide attempt and no completed suicides among TESI participants during the study Relationship of TESI with venlafaxine doses and levels.
Mean ( + SD) venlafaxine dose at the time of TESI was 132.8 + 48.2 mg/day (median: 150 mg/day; range 75-300 mg/day), reflecting the typical time of onset of TESI and the titration protocol.
There were no significant differences in venlafaxine (p = 0.87) or O-desmethylvenlafaxine levels (p = 0.51) between the participants with or without TESI (Table 1) . Table 1 shows sociodemographic, clinical, and neuropsychological characteristics of TESI and non-TESI participants. These univariate comparisons indicated that TESI participants had higher medical comorbidity scores, higher baseline MADRS scores, and higher baseline ASI and PSWQ anxiety scores that were significantly different from non-TESI participants. A final logistic regression model with TESI as dependent variable indicated that baseline ASI scores (p = 0.004) and baseline MADRS scores (p = 0.004) remained significant predictors of TESI controlling for site. This model indicated that subjects with higher baseline ASI scores were more likely to develop TESI (Odds ratio = 1.04, confidence interval 1.00-1.08), and subjects with higher MADRS at baseline were more likely to develop TESI (Odds ratio = 1.13, confidence interval 1.04-1.24) controlling for site.
Clinical correlates of TESI
Changes in clinical variables at the time of TESI
The relationship between worsening of depression or worsening of anxiety and TESI was explored using a linear mixed effect model with time continuous. Neither MADRS (mean ± SD: 28.5 ± 5.4 at baseline vs. 27.2 ± 7.9 at onset of TESI; F(1,23) = 0.66, p = 0.43) nor BSI-anxiety scores (mean ± SD: 1.7 ± 1.0 at baseline vs. 1.5 ± 1.1 at onset of TESI; F(1,23) = 0.70, p = 0.41) were significantly higher at the time of onset of TESI than at baseline. 
Treatment outcomes and tolerability
To assess treatment outcomes between subjects developing TESI and those who did not, we analyzed MADRS scores over time using a mixed effects model. As shown in Figure 2 , there was a statistically significant group by time interaction indicating there was a slower improvement in depressive symptoms over time in subjects who developed TESI than in those who did not. In addition, we examined categorical treatment outcomes at the end of the open label phase using chi-square tests comparing remission rates between TESI and non-TESI groups as well as study withdrawal rates due to side effects and due to other reasons between these groups. No statistical differences were found between groups (Table 2) .
Last, we estimated the frequency of side effects at the time of onset of TESI. A total of 12 participants in the TESI group reported the following side effects: gastro-intestinal disturbances (n = 5), sleep disturbances (n = 5), fatigue (n = 4), appetite/weight changes (n = 2), tremor (n = 2), sweating (n = 2), dizziness (n = 2), drowsiness (n = 2), and others (n = 1). These side effects were consistent with venlafaxine's side effect profile.
Clinical vignettes of clinically meaningful TESI
Among the 24 participants who developed emergent suicidal ideation, most (18/24) had only a transient and modest increase in SSI (i.e., score = 1 at only 1 or 2 time points) and were therefore determined to be of doubtful clinical significance. There were six cases (2.6% of sample) with clinically meaningful TESI for which we further reviewed their data including clinician notes. These six cases are described below, to provide clinical context regarding clinically meaningful TESI.
Case 1
• Retired, 74 year old married, African American female.
• Past history of recurrent MDD and previous suicide attempts.
• Current depressive episode duration of 9 months with baseline MADRS score of 16.
• Four weeks into treatment her depression worsened (MADRS = 32) and she endorsed suicidal ideation (SSI = 20). At that time venlafaxine dose was 150 mg/day. She was hospitalized and made a suicide attempt while inpatient. Venlafaxine was further increased to 300 mg/day. Suicidal ideation resolved (SSI score = 0) after 12 weeks of treatment and she was a remitter (MADRS = 2) at her last assessment.
Case 2
• Retired 74 year old married, Caucasian female.
• Past history of recurrent MDD and past history of suicidal ideation.
• Current episode had lasted 12 months and she scored 29 on the initial MADRS.
• Six weeks into treatment, while receiving venlafaxine 150 mg/day her depression was unchanged (MADRS = 26) and she endorsed mild suicidal ideation (SSI = 1). Further increase in venlafaxine up to 300 mg/day, was not helpful. Her depression remained high with a MADRS score of 31 and continuous endorsement of mild suicidal ideation (SSI score = 2) by the end of treatment.
Case 3
• A 60 year old separated, Caucasian female. She was on disability insurance from work related injury.
• This was her first major depressive episode, with current high severity (baseline MADRS = 34) and long duration (78 months). Past history of suicidal ideation.
• Highest point of suicidal ideation (SSI score = 7) occurred 6 weeks into treatment with venlafaxine 112.5 mg/day. A further increase in venlafaxine up to 300 mg/day yielded modest improvement (MADRS = 25), although suicidal ideation decreased it remained persistent with a SSI score of 1 at the end of treatment.
Case 4
• An 85 year old widowed, Caucasian female.
• History of recurrent MDD and past suicidal ideation.
• Current episode was of moderate severity (MADRS = 21) and had lasted 22 months. After 12 weeks of treatment she reported suicidal ideation (SSI score = 8) while on venlafaxine 150 mg/ day and scored 8 on the SSI. At the end of treatment her mood wad worsened (MADRS = 24).
Case 5
• A retired 68 year old married, Caucasian female.
• History of recurrent MDD, no previous suicidal ideation or attempts.
• Current episode was severe (MADRS = 30) and had lasted 30 months.
• She had difficulties cross-titrating off citalopram onto venlafaxine with reported dizziness and weakness. After 2 weeks of treatment she endorsed suicidal ideation with a high score of 10 on the SSI and worsening mood (MADRS = 32). Venlafaxine dose at the time was 112.5 mg/day. She could not tolerate further titration and was tapered off after 12 weeks. While most of her symptoms remained high (MADRS = 32) her suicidal ideation subsided (SSI = 0). She experienced increase in anxiety and dizziness and was ultimately withdrawn from the study.
Case 6
• A retired 61 year old married, Caucasian male.
• First major depressive episode with recent suicide attempt months before study start.
• Current episode was severe with a MADRS score of 35.
• At study start he was cross-titrated off duloxetine and olanzapine onto venlafaxine. Two weeks into treatment he reported suicidal ideation (SSI score = 11) and worsening depression (MADRS = 41). At this time he was diagnosed with a urinary tract infection and experienced severe dysuria and incontinence. By the end of treatment his depression remained high (MADRS = 37) and he endorsed persistent suicidal ideation (SSI score = 9).
Replication sample
To examine the generalizability of our findings, we reviewed data from a previous treatment study (Reynolds et al., 2010) in which all subjects received a 16-week acute course of escitalopram. Suicidal ideation was assessed weekly with the SSI. From 122 participants who received escitalopram, 113 had no baseline suicidal ideation; of these, 10 (8.9%) developed TESI. Mean time to TESI was 11.2 weeks (standard error = 0.22). At the time of TESI, mean SSI scores were 2.0 (SD = 1.2), median = 1.5, range = 1-4. Baseline sociodemographic and clinical characteristics of this sample were as follows: mean age of 74 years (SD 6.0), 76.1% were females, most were Caucasians 89.4%, mean education of 13.5 (SD 2.6) years and their burden of illness according to the CIRGS-G was 10.5 (SD 3.4). In terms of depression history, 41.1% had recurrent depression, mean age of depression onset was 59.4 years (SD 19.1) and mean duration of the current depressive episode was 150.9 weeks (SD 378.5).
Discussion
In older adults with major depression followed prospectively during an open-label venlafaxine trial, the rate of TESI was 10%. TESI typically occurred early in treatment (within 4 weeks of venlafaxine initiation) and was mostly of mild severity, with only six (2.6%) participants who experienced more severe or more persistent TESI. The 10% and 2.6% incidence rates are much higher than the incidence (.53%) reported in a meta-analysis of 372 double blind randomized controlled trials of 12 antidepressants (including venlafaxine) in mixed-age adults (Stone et al., 2009) . A likely explanation for this much higher rate of TESI in our study was our systematic screening for suicidal ideation using the SSI at each weekly visit, and our liberal definition of TESI, requiring only a single SSI score ≥ 1. Supporting this assertion, Courtet et al. reported a 8.8% rate of new onset suicidal ideation in mixed aged (mean = 47 years-old) depressed outpatients in France. (REF Courtet et al.) using a methodology akin to ours. By comparison, we found a TESI rate of 8.9% in the escitalopram replication sample. However, we cannot rule out the possibility that the higher rate of TESI in our older adults is related to the fact that late life depression may be a biologically distinct entity characterized by persistent cognitive symptoms, CNS inflammatory changes, and reduced neurotrophic support (Alexopoulos and Morimoto, 2011; Teixeira et al., 2010; Diniz et al., 2015) .
We observed the onset of TESI predominantly during the first few weeks of treatment. This is congruent with another study (Jick et al., 2004) reporting the highest risk of suicidal behavior within 9 days of starting antidepressants. The investigators proposed that because antidepressants take time to work, the risk appears higher in newly diagnosed and treated patients than in those treated for a longer time. It is also possible that patients who initially conceal their suicidality feel more comfortable reporting it after a few visits during which they have established a rapport with a clinician.
Regarding the question of whether TESI may be due to the antidepressant, previous research indicated antidepressant blood levels are associated with suicidal ideation during treatment. Perroud et al., 2011 reported a positive correlation between paroxetine and clomipramine blood levels and suicidal ideation. We examined whether higher levels of venlafaxine and O-desmethylvenlafaxine correlated with TESI, but found no differences between levels in participants who developed TESI versus those that did not, implying the level of medication exposure was not a driving factor for TESI. We also examined side effects in the TESI group for evidence of increased anxiety, irritability, or psychomotor agitation which have been previously related to suicidality (Szanto et al., 2007; Akiskal et al., 2005; Balazs et al., 2006) . In our sample, we did not observe increases in anxiety at the time of TESI. Similarly, we did not find that other side effects coincided with the onset of TESI. Furthermore, as an indirect measure of antidepressant's tolerability, we examined the rate of withdrawals from the study due to side effects. We found that the rate of withdrawal from the study in those subjects developing TESI was not different from those who did not. Together, these findings prompt to examine other mechanisms of TESI vulnerability in depressed older adults such as those related to illness severity or genetic predisposition.
In terms of baseline clinical characteristics, higher comorbid medical burden, anxiety, and higher depression severity were associated with new onset TESI in univariate analysis. The final logistic regression model indicated that higher depression scores and higher anxiety scores at baseline were the most definitive predictors of TESI. These findings agree with Zisook et al. (2009) who found that depression severity, concurrent substance abuse and melancholia were associated with TESI in a report from the STAR*D trial. Likewise, other studies have pointed at depression severity, medical, and psychiatric comorbidity (including anxiety) as predictors of suicidal ideation independent of treatment (Alexopoulos et al., 2009; Bogers et al., 2013; Shah et al., 2000; Lenze et al., 2000; Seo et al., 2011) In contrast with other studies reporting worsening of depression in association with suicidal ideation during antidepressant treatment (Perroud et al., 2011; Courtet et al., 2014; Perlis et al., 2007) , we found that depression worsening did not coincided with the onset of TESI. Furthermore, our mixed effects model depicting the trajectory of depressive symptoms over the course of treatment indicated that subjects who developed TESI had higher depression scores at baseline and slower improvement than those who did not develop TESI, indicating a more severe and treatment resistant depression course.
Taken together, these results suggest TESI occurred in those with a more complex psychiatric illness indicating that TESI was more related to the clinical presentation rather than to the antidepressant. If indeed, TESI represents a feature of treatment resistance, findings from the IRL-GREY study (Lenze et al., 2015) showing reduction in suicidal ideation with aripiprazole augmentation can guide clinicians in considering second-generation antipsychotic augmentation in high risk treatment resistant patients (Meltzer et al., 2003) .
Finally, our baseline evaluation of neurocognitive function indicated overall lower global cognitive function in the TESI group than in the Non-TESI, but no statistical differences between groups in either global cognitive function or executive function. This information differs from the findings from RichardDevantoy et al. (2012) who found executive function impairments, specifically in cognitive inhibition, in depressed inpatient elderly with a recent suicide attempt. Likewise, our findings deviate from Gujral et al. (2013) who found increased global deficits and executive deficits in elderly who had attempted suicide and serious suicidal ideators (those who endorsed suicidal ideation and plan). Last, we did not find statistical associations on cognitive measures despite a recent trajectory analysis by Kasckow et al. (2015) reporting that deficits in global cognitive function, attention and executive function were predictors of membership in a "high and persistent suicidal ideation trajectory". We posit that the failure to find statistical differences on cognitive variables between TESI and non-TESI group may be attributed to the low severity of suicidal ideation in our sample, the fact that these were outpatients as opposed to inpatients (as in studies by Richard-Devantoy and Gujral) and the low number of TESI participants.
In summary, in this sample of depressed older adults, TESI was associated with the severity and complexity of the depressive illness. It did not appear to be an adverse effect of the exposure to venlafaxine, as there was no relationship between TESI and blood levels or side effects. The limitations of the study include the small number of participants with TESI, lack of a placebo control group, and lack of other psychosocial measures including social support. Nevertheless, our findings are important because they support that TESI is a common feature of severe and treatmentresistant depression in older adults, and that clinicians should stay the course of treatment.
